The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

ASPET

SEPTEMBER 16, 2024

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

AUGUST 4, 2023

131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy. Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients.

Pharmacogenetics 100

Pharmacogenetics Therapies Disease 100